Literature DB >> 14688049

Antibiotic prophylaxis, body piercing and infective endocarditis.

Beverley C Millar1, John E Moore.   

Abstract

Infective endocarditis (IE) is associated with a high degree of morbidity and mortality and generally presents in patients with altered and abnormal heart architecture combined with exposure to bacteria through trauma and other potentially high-risk activities, including body piercing. Modern social behaviour has resulted in increased popularity of the practice of body piercing, particularly amongst the adolescent population and there has been a marked rise of cases of IE directly attributable to this practice. In this article we wish to examine the aetiology of such cases reported in the literature, with particular emphasis on causal organism, as well as to discuss the role of antibiotic prophylaxis and awareness in such at-risk patients within the primary care community.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688049     DOI: 10.1093/jac/dkh034

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  [Piercing the heart].

Authors:  E Rojo Rodríguez; A Rodríguez Rodríguez; S Pérez Cachafeiro
Journal:  Aten Primaria       Date:  2005-03-15       Impact factor: 1.137

2.  Bacterial infections complicating tongue piercing.

Authors:  Catherine Hy Yu; Brian J Minnema; Wayne L Gold
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature.

Authors:  Battagin Giuliana; Sarmati Loredana; Sordillo Pasquale; Picchi Giovanna; Calisti Giorgio; Ceccarelli Laura; Antonio Pellegrino; Nardi Paolo; Chiariello Luigi; Andreoni Massimo
Journal:  Cases J       Date:  2010-01-25

4.  Infective endocarditis in previously healthy children with structurally normal hearts.

Authors:  Daphna Marom; Shai Ashkenazi; Zmira Samra; Einat Birk
Journal:  Pediatr Cardiol       Date:  2013-03-13       Impact factor: 1.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.